PDSB - PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16- Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
PDSB - PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16- Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology